Human Glioblastoma Cancer Stem Cells Differentiation by Retinoic Acid: A Potential Therapeutic Strategy

Overview

Glioblastoma is an aggressive and fatal brain cancer, with a median survival of 15 months despite current treatments. Conventional therapies focus on eliminating cancer cells, but alternative strategies are needed. Retinoic Acid (RA), a vitamin A derivativ e, is known to induce cellular differentiation and is successfully used in treating Acute Promyelocytic Leukemia. However, its effects on Glioblastoma stem cells remain unclear. We hypothesized that RA could promote the differentiation of human Glioblastom a stem cells into neurons, potentially offering a novel therapeutic approach. LN -229 and U87 -MG Glioblastoma stem cells were treated with RA at concentrations of 1.25, 2.5, 5, and 10 µM in media containing either 2% or 10% Fetal Bovine Serum (FBS). After 24 hours of incubation, cells were treated for five days, fixed, and stained with DAPI (stains all cell nuclei) and TUJ1 (beta tubulin antibody) to assess neuronal differentiation under fluorescence microscope. Cells were stained for viability using FDA (fluorescent diacetate). Our study showed that RA effectively induces differentiation of Glioblastoma stem cells into neurons with U87 -MG cells exhibiting a stronger response than LN-229. RA at 2.5 and 5 µM induced differentiation in both cell lines, with the most pronounced effect observed at 5 µM in 10% FBS. Lower concentrations (1.25 µM) inhibited cell growth, while higher doses (10 µM) led to cell death. The combination of 5 µM RA and 10% FBS yielded the best differentiation, highlighting its potential as a therapeutic strategy. Further in vivo studies are warranted to explore its clinical applications in Glioblastoma patients.

Competition history

• JSHS 2025 Category not listed

Resources

• National JSHS abstract book ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.